BioNTech SE Files SC 13D on Autolus Therapeutics Stake

TL;DR

**BioNTech just filed a 13D on Autolus Therapeutics, signaling continued strategic interest!**

AI Summary

BioNTech SE filed an SC 13D on February 21, 2024, regarding its ownership in Autolus Therapeutics plc. The filing indicates BioNTech SE's continued interest in Autolus Therapeutics, a company specializing in biological products. The securities involved are Autolus Therapeutics' ordinary shares, including those represented by American Depositary Shares, with a CUSIP number of 05280R100.

Why It Matters

This filing signals BioNTech SE's ongoing strategic interest in Autolus Therapeutics, potentially impacting future collaborations or investment decisions in the biotech sector.

Risk Assessment

Risk Level: low — This is a routine disclosure of ownership, not indicating any immediate high-risk events.

Key Numbers

• $0.000042 — Nominal Share Value (Nominal value per ordinary share of Autolus Therapeutics plc)

Key Players & Entities

• BioNTech SE (company) — Filing entity, owner of shares
• Autolus Therapeutics plc (company) — Subject company, issuer of securities
• Prof. Ugur Sahin, M.D. (person) — Contact person for BioNTech SE
• $0.000042 (dollar_amount) — Nominal value per ordinary share of Autolus Therapeutics plc
• 05280R100 (company) — CUSIP Number for Autolus Therapeutics plc securities

FAQ

Key Financial Figures

• $0.000042 — ssuer) Ordinary shares, nominal value $0.000042 per share (including ordinary shares
• $6.00 — itial Purchase ) at a purchase price of $6.00 per ADS on February 13, 2024. The total
• $200,000,000 — sideration for the Initial Purchase was $200,000,000. Under the Purchase Agreement, BioNTech
• $20,000,000 — DSs with an aggregate purchase price of $20,000,000, up to a maximum of 15,000,000 ADSs (th
• $6 — ice per Ordinary Share or ADS less than $6.00, the right to purchase up to 20% of

Filing Documents

• d782522dsc13d.htm (SC 13D) — 53KB
• 0001193125-24-041581.txt ( ) — 55KB

From the Filing

SC 13D 1 d782522dsc13d.htm SC 13D SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.)* Autolus Therapeutics plc (Name of Issuer) Ordinary shares, nominal value $0.000042 per share (including ordinary shares represented by American Depositary Shares)** (Title of Class of Securities) 05280R100*** (CUSIP Number) Prof. Ugur Sahin, M.D. An der Goldgrube 12 D-55131 Mainz Germany Tel: +49 6131-9084-0 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) February 13, 2024 (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7(b) for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. ** The Reporting Persons own ordinary shares through the Issuers American Depositary Shares, each representing one ordinary share. *** The ordinary shares have no CUSIP number. The CUSIP number for the Issuers American Depositary Shares, each representing one ordinary share, is 05280R100. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SCHEDULE 13D CUSIP No. 05280R100 Page 2 of 7 1 NAME OF REPORTING PERSONS BioNTech SE 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a)(b) 3 SEC USE ONLY 4 SOURCE OF FUNDS (See Instructions) OO 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) 6 CITIZENSHIP OR PLACE OF ORGANIZATION Federal Republic of Germany NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 33,333,333 Ordinary Shares (represented by 33,333,333 ADSs) 8 SHARED VOTING POWER 0 9 SOLE DISPOSITIVE POWER 33,333,333 Ordinary Shares (represented by 33,333,333 ADSs) 10 SHARED DISPOSITIVE POWER 0 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 33,333,333 Ordinary Shares (represented by 33,333,333 ADSs) 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 12.5% 14 TYPE OF REPORTING PERSON (See Instructions) OO ( Societas Europaea organized and existing under the laws of Germany) Item1. Security and Issuer This Schedule 13D (the Schedule 13D ) relates to the ordinary shares, nominal value $0.000042 per share (the Ordinary Shares ), represented by American Depositary Shares (the ADSs ), each of which represents one Ordinary Share, of Autolus Therapeutics plc, a public limited company organized under the laws of England and Wales (the Issuer ). The address of the principal executive office of the Issuer is The MediaWorks, 191 Wood Lane, London W12 7FP, United Kingdom. Item2. Identity and Background (a) This Schedule 13D is being filed by BioNTech SE, a Societas Europaea organized and existing under the laws of Germany ( BioNTech or the Reporting Person ). (b) The principal business address of the Reporting Person is An der Goldgrube 12, D-55131 Mainz, Germany. (c) BioNTech is a biopharmaceutical company pioneering novel therapies for cancer and other serious diseases. The name, business address, present principal occupation or employment and citizenship of each member of the Management Board and each member of the Supervisory Board of the Reporting Person are set forth on Schedule I attached hereto. (d) (e) During the last five years, neither the Reporting Person nor, to the knowledge of the Reporting Person, any person named in Schedule I has been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (f) The jurisdiction of organization of the Reporting Person is set f

View Full Filing

View this SC 13D filing on SEC EDGAR